Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:37:25 EST Wed 18 Nov 2026
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR+ Search
SEDAR+ Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR+ Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login ID:
Password:
Save
Q:CVKD
- CADRENAL THERAPEUTICS INC -
Website unknown - click to update
08:37:25 EST
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
CVKD
- Q
0.1
1.67
·
1.84
0.8
1.88
8.9
12
24
12.50 0.8163
08:14:23
Oct 07
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Portfolio
Recent Trades - Last 10 of 24
More trades...
Time ET
Ex
Price
Change
Volume
08:14:23
Q
1.8216
-0.0584
1
08:08:40
Q
1.84
-0.04
200
08:08:40
Q
1.8104
-0.0696
200
08:08:19
Q
1.84
-0.04
3
08:07:47
Q
1.82
-0.06
1
08:07:47
Q
1.82
-0.06
1
08:07:47
Q
1.84
-0.04
1,013
08:07:47
Q
1.84
-0.04
285
08:07:47
Q
1.84
-0.04
700
07:53:09
Q
1.84
-0.04
15
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2026-10-07 07:00
U:CVKD
News Release
200
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
2026-09-21 16:30
U:CVKD
News Release
200
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
2026-09-03 08:00
U:CVKD
News Release
200
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
2026-08-31 08:00
U:CVKD
News Release
200
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
2026-08-13 16:15
U:CVKD
News Release
200
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
2026-08-03 08:30
U:CVKD
News Release
200
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation
2026-07-21 08:00
U:CVKD
News Release
200
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
2026-07-13 09:00
U:CVKD
News Release
200
Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
2026-06-30 20:01
U:CVKD
News Release
200
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2026-06-24 08:00
U:CVKD
News Release
200
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
2026-06-18 09:00
U:CVKD
News Release
200
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
2026-06-15 08:30
U:CVKD
News Release
200
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
2026-06-03 09:00
U:CVKD
News Release
200
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
2026-05-19 16:30
U:CVKD
News Release
200
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
2026-05-07 08:30
U:CVKD
News Release
200
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
2026-04-30 08:30
U:CVKD
News Release
200
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
2026-03-31 08:45
U:CVKD
News Release
200
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
2026-03-12 08:00
U:CVKD
News Release
200
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
2026-03-02 08:00
U:CVKD
News Release
200
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
2026-02-24 08:30
U:CVKD
News Release
200
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement